#United States #Cambridge #KTX-1001 #K36 Therapeutics #Multiple Myeloma

K36 Therapeutics Presents New Data on KTX-1001

K36 Therapeutics, Inc., a clinical-stage biotech firm based in Cambridge, has announced its participation in the 22nd Annual International Myeloma Society (IMS) Meeting in Toronto, showcasing new preclinical data for its candidate drug KTX-1001. This novel therapy is currently undergoing evaluation for patients grappling with relapsed or refractory multiple myeloma (MM), a condition particularly hard to treat. The event takes place from September 17-20, 2025, and the company will present two detailed posters highlighting the significance of KTX-1001’s mechanism and its potential efficacy.

KTX-1001 acts as a selective inhibitor of NSD2, a histone methyltransferase that is notably dysregulated in multiple myeloma patients harboring the t(4;14) chromosomal translocation. This genetic anomaly marks an aggressive subtype of the disease, associated with poorer prognosis and limited responses to existing standard-of-care treatments. Currently, K36 is enrolling patients in an ongoing Phase 1b trial assessing the combination of KTX-1001 with both traditional therapies and mezigdomide targeting this vulnerable subset of MM patients.

The information shared at the IMS Meeting is expected to underscore the unique action of KTX-1001. The focus will be on bone marrow analyses from ongoing clinical trials, which are instrumental in connecting scientific understanding with new therapeutic possibilities. Moreover, large-scale omics datasets indicate that there exists a separate group of newly diagnosed patients exhibiting high NSD2 expression, even in the absence of the t(4;14) translocation. This discovery opens doors for further testing of NSD2 inhibitors in a broader patient population who face these significant treatment challenges.

Dr. Erin Flynt, Executive Director of Translational Medicine at K36 Therapeutics, emphasized the importance of these findings, stating, "The data strengthen the rationale for KTX-1001, showcasing its unique mechanism in a clinical context. Recognizing high NSD2 levels in patients beyond the t(4;14) demographic enhances our clinical development strategy and could vastly improve therapeutic outcomes for multiple myeloma patients."

Poster Highlights

1. Title: Anti-adhesion Properties of KTX-1001, a Selective NSD2/MMSET Inhibitor, Enhance Carfilzomib Sensitivity in Multiple Myeloma
Poster Number: PA-293
Location: Exhibit Hall, Hall E
Presentation Time: Friday, September 19, 12:15 - 1:15 p.m. ET

2. Title: High Expression of NSD2 in Non-t(4;14) Newly-diagnosed Multiple Myeloma Patients May Mimic t(4;14) Biology
Poster Number: PA-259
Location: Exhibit Hall, Hall E
Presentation Time: Thursday, September 18, 12:00 – 1:00 p.m. ET

The full abstracts of these presentations can be accessed through the IMS Annual Meeting website, providing a comprehensive overview of K36 Therapeutics’ groundbreaking research in multiple myeloma treatment.

About KTX-1001

KTX-1001 is envisioned as a first-in-class treatment, crafted as an oral small molecule that selectively targets MMSET/NSD2 enzymatic activity. Initially developed for patients suffering from relapsed and refractory multiple myeloma, the treatment holds particular promise for those possessing the aggressive t(4;14) translocation. K36 Therapeutics is dedicated to addressing the pressing needs of this patient demographic, which has seen little progress in therapeutic options.

Context: Multiple Myeloma

Multiple myeloma is recognized as the second most prevalent hematologic cancer, characterized by unregulated plasma cell proliferation within the bone marrow. The American Cancer Society notes around 36,000 new diagnoses each year. Despite advancements in treatment that have extended survival rates, the disease remains incurable, and patients frequently experience relapse. The high-risk category, driven by genetic mutations such as t(4;14), presents one of the most substantial challenges in myeloma therapy, necessitating innovative strategies like KTX-1001.

About K36 Therapeutics

Established in February 2021, K36 Therapeutics is a biotech company propelled by investments from prominent entities including Atlas Venture, F-Prime, and Bristol Myers Squibb. Committed to transforming the landscape of cancer treatment, the company focuses on translating insights from epigenetic modulation into innovative therapies designed to offer widespread benefits for patients battling various forms of cancer. To learn more about their initiatives, visit www.k36tx.com

For media inquiries, reach out to:

• - Soo Bang, K36 Therapeutics, Email: [email protected]
• - Sarah Sutton, Media Relations, Phone: (518) 932-3680, Email: [email protected]